BIONOMICS LIMITED - AMERICAN DEPOSITORY SHARES

Bionomics Limited Announces Private Placement of up to $70.0 Million

31 May 2024 07:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

20 May 2024 05:30:00 By Nasdaq GlobeNewswire

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

21 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at the 2024 BIO CEO & Investor Conference

22 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Bionomics Provides a Review of 2023 and of 2024 Plans

22 Jan 2024 05:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at Biotech Showcase™ 2024

05 Jan 2024 05:00:00 By Nasdaq GlobeNewswire

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

28 Sep 2023 05:00:52 By Nasdaq GlobeNewswire

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

14 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

23 Aug 2023 05:00:00 By Nasdaq GlobeNewswire

Quarterly Activities and Cashflow Report

31 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

03 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Bionomics to Present at Upcoming June Investor Conferences

15 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

30 May 2023 05:00:00 By Nasdaq GlobeNewswire

Quarterly Activities and Cashflow Report

28 Apr 2023 05:00:00 By Nasdaq GlobeNewswire

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

27 Apr 2023 05:00:00 By Nasdaq GlobeNewswire

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

08 Mar 2023 18:00:30 By Nasdaq GlobeNewswire

Bionomics’ Half-Year Report

23 Feb 2023 05:00:00 By Nasdaq GlobeNewswire

Quarterly Activities and Cashflow Report

30 Jan 2023 17:23:46 By Nasdaq GlobeNewswire